At the tumor site, BMDSCs also have the capacity to differentiate into angiogenesis-promoting endothelial cells [76, 77], or TAFs [78] as a source of extracellular protease expression, TGF-β, VEGF, CXCL-12, -14, -16, CCL2-5, IL-4 or IL-6 [79, 80], the collective interplay of which contributes to tumor progression. Here, CCL25 is linked to neoplasm.